Want to see HYPR full AI Analyst Report?
Top Page
Hyperfine
(NASDAQ:HYPR)
Select Model
Select Model
Rating:54Neutral
Price Target:
$0.76
▼(-12.53% Downside)
Action:Reiterated
Date:10/09/26
The score is held back primarily by weak financial performance (large losses and negative free cash flow despite improving gross margin) and limited valuation support (negative P/E, no dividend). Offsetting factors include improving operational momentum and reiterated guidance from the latest earnings call, plus constructive near-term technicals, though longer-term price trends and Nasdaq compliance risk remain notable overhangs.
Positive Factors
Revenue and Placement Growth
Strong revenue and unit-placement growth indicates expanding adoption of Hyperfine’s portable MRI platform across healthcare settings. Continued commercial traction can improve fixed-cost absorption, strengthen customer references, and support the company’s reiterated 2026 growth outlook.
Negative Factors
Persistent Losses and Cash Burn
Large ongoing losses and deeply negative operating and free cash flow show that the current revenue base does not yet support the business’s cost structure. Continued cash consumption may require sustained spending discipline or future financing before self-funded profitability is achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Placement Growth
Strong revenue and unit-placement growth indicates expanding adoption of Hyperfine’s portable MRI platform across healthcare settings. Continued commercial traction can improve fixed-cost absorption, strengthen customer references, and support the company’s reiterated 2026 growth outlook.
Read all positive factors
Hyperfine (HYPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$79.14M
Dividend YieldN/A
Average Volume (3M)964.97K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue Growth53.16%
EPS Growth27.17%
CountryUS
Employees102
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.38
Shares Outstanding90,993,380
10 Day Avg. Volume1,795,021
30 Day Avg. Volume964,971
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.25
Price to Sales (P/S)6.80
P/FCF Ratio-3.17
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue6.25
Enterprise Value/Gross Profit12.16
Enterprise Value/Ebitda-3.12
Forecast
1Y Price Target
$2.03Price Target Upside133.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$20.17M
Hyperfine Business Overview & Revenue Model
Company Description
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength t...
Hyperfine Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and commercial progress: double-digit revenue and unit growth, sustained gross margins above 50%, improved cash burn, strengthened balance sheet via ATM proceeds, meaningful clinical evidence (PRIME, NEURO PMR), regulatory approvals (CE/UKCA) and clear product roadmaps (contrast labeling, AI-enabled software). Notable challenges remain, including a sizable ongoing net loss, persistent (though improving) cash burn, modest absolute revenue and unit volume, timing sensitivity to IDN budget cycles, and pending regulatory label expansion for contrast. Management reiterated full-year guidance and emphasized identifiable growth drivers, suggesting confidence in conversion of recent momentum into scale.Positive Updates
Strong Revenue Growth
Q2 revenue of $3.9M, up ~45% year-over-year from $2.7M; first half revenue $7.8M, up ~62% year-over-year from $4.8M. Company reiterated full-year 2026 revenue guidance of $20M–$22M (midpoint ≈ 55% YoY growth).
Negative Updates
Continued Net Loss
Net loss of $9.3M in Q2 (loss per share $0.09) compared to $9.2M a year ago (loss per share $0.12). Loss included $0.6M non-cash loss from change in fair value of warrant liabilities.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Q2 revenue of $3.9M, up ~45% year-over-year from $2.7M; first half revenue $7.8M, up ~62% year-over-year from $4.8M. Company reiterated full-year 2026 revenue guidance of $20M–$22M (midpoint ≈ 55% YoY growth).
Read all positive updates
Company Guidance
Hyperfine reiterated full-year 2026 guidance of $20.0–$22.0 million in revenue (midpoint implying ~55% YoY growth), gross margin of 50–55% for the year, and total cash burn of $26–$28 million (≈10% YoY decline at the midpoint), and said its cash runway extends into 2028. Management pointed to supporting results in the first half—Q2 revenue $3.9M (up ~45% YoY) and H1 revenue $7.8M (up ~62% YoY), Q2 unit sales 12 (up 50% YoY) and H1 units 22 (up ~57% YoY), Q2 gross margin 50.7% (fourth consecutive quarter >50%, +150 bps YoY), and improving cash burn (Q2 net cash burn excl. financing $7.9M; H1 $16.6M, down ~9% YoY). As of June 30, 2026 the company had $43.5M cash, a $2.7M quarterly increase that included $10.6M of ATM proceeds at an average $1.52/share, and cited identifiable second-half drivers (Model 2 adoption, hospital/IDN conversions, office growth, international rollout, clinical/economic evidence, software and contrast labeling catalysts) supporting the guidance.Hyperfine Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.54M | 13.56M | 12.89M | 11.03M | 6.81M | 1.50M |
| Gross Profit | 8.50M | 6.75M | 5.89M | 4.76M | 907.00K | -1.17M |
| EBITDA | -33.12M | -34.48M | -39.71M | -43.18M | -72.15M | -64.13M |
| Net Income | -34.85M | -35.57M | -40.72M | -44.24M | -73.16M | -64.83M |
Balance Sheet | ||||||
| Total Assets | 63.00M | 55.26M | 58.90M | 94.20M | 134.05M | 202.47M |
| Cash, Cash Equivalents and Short-Term Investments | 43.46M | 35.09M | 37.65M | 75.18M | 118.24M | 188.50M |
| Total Debt | 13.41M | 314.00K | 269.00K | 185.00K | 0.00 | 0.00 |
| Total Liabilities | 26.24M | 14.26M | 9.86M | 9.80M | 10.33M | 16.25M |
| Stockholders Equity | 36.76M | 41.01M | 49.04M | 84.40M | 123.72M | 186.23M |
Cash Flow | ||||||
| Free Cash Flow | -27.53M | -29.13M | -39.15M | -42.61M | -72.92M | -49.89M |
| Operating Cash Flow | -27.07M | -27.95M | -38.77M | -41.81M | -72.34M | -47.18M |
| Investing Cash Flow | -465.00K | -1.19M | -383.00K | -804.00K | -585.00K | -2.71M |
| Financing Cash Flow | 46.72M | 27.50M | 1.02M | 174.00K | 7.00K | 176.77M |
Hyperfine Technical Analysis
Negative
0.87
Price Trends
0.83
Negative
1.01
Negative
1.14
Negative
Market Momentum
-0.02
Positive
35.02
Neutral
8.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPR, the sentiment is Negative. The current price of 0.87 is above the 20-day moving average (MA) of 0.83, above the 50-day MA of 0.83, and below the 200-day MA of 1.14, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 35.02 is Neutral, neither overbought nor oversold. The STOCH value of 8.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HYPR.
Hyperfine Risk Analysis
Hyperfine disclosed 79 risk factors in its most recent earnings report. Hyperfine reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Hyperfine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $1.12B | 48.25 | 23.45% | 1.45% | 11.21% | 11.08% | |
58 Neutral | $1.98B | -24.53 | -38.36% | ― | 28.14% | -5.15% | |
56 Neutral | $1.06B | -15.42 | -44.85% | ― | 31.70% | -28.13% | |
54 Neutral | $79.14M | -1.95 | -100.30% | ― | 53.16% | 27.17% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $288.26M | -7.84 | -188.09% | ― | 25.86% | -47.31% | |
44 Neutral | $32.48M | -0.23 | -94.35% | ― | 31.52% | -89.07% |
* Healthcare Sector Average
HYPR
Hyperfine
0.75
-0.50
-40.32%
CLPT
ClearPoint Neuro
9.25
-16.02
-63.40%
IRMD
Iradimed
87.81
10.92
14.21%
BFLY
Butterfly Network
7.10
4.88
219.82%
NNOX
Nano-X Imaging
0.38
-3.71
-90.61%
CBLL
Ceribell, Inc.
27.14
14.20
109.74%
Hyperfine Corporate Events
Business Operations and StrategyFinancial Disclosures
Hyperfine Reports Record Q3 Revenue and Reduced Cash Burn
Positive
Oct 8, 2026
On October 8, 2026, Hyperfine reported preliminary third-quarter 2026 revenue of about $6.0 million, a record for the company and a 53% sequential increase over the prior quarter. The growth was driven by momentum across its three commercial verti...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Hyperfine Receives Nasdaq Minimum Bid Price Deficiency Notice
Negative
Sep 18, 2026
On September 17, 2026, Hyperfine, Inc. was notified by Nasdaq that its Class A common stock no longer met the minimum $1.00 bid price requirement after trading below that threshold for 30 consecutive business days. The stock remains listed and tra...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.